deferiprone has been researched along with Hemosiderosis in 23 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Hemosiderosis: Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Data from several trials have provided direct and supportive evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major." | 4.79 | Long-term therapy with deferiprone. ( Olivieri, NF, 1996) |
| " In thalassemia major patients, combined therapy with desferrioxamine and deferiprone has maximized tissue iron removal and may reduce the overall occurrence of hemosiderotic heart failure." | 3.73 | Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M, 2005) |
| "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
| "The oral iron chelator deferiprone (1,2-dimethyl-3-hydroxy-pyrid-4-one, DMHP, LT or CP20) can be a useful drug in patients with transfusional hemosiderosis." | 3.69 | Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1). ( de Kaste, D; Lameijer, W; Lange, R; Slijkhuis, C, 1996) |
| "Deferiprone was clearly not effective in three patients (two with myelofibrosis, one with myelodysplasia)." | 2.68 | Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. ( Goudsmit, R; Kersten, MJ; Lameijer, W; Lange, R; Roozendaal, KJ; Smeets, ME; Vreugdenhil, G, 1996) |
| "Deferiprone is an iron chelator that has recently been used to treat patients with infratentorial superficial siderosis (iSS)." | 1.56 | Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis. ( Banerjee, G; Cowley, P; Eleftheriou, P; Farmer, S; Hylton, B; Porter, J; Sammaraiee, Y; Werring, DJ, 2020) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 10 (43.48) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Sammaraiee, Y | 1 |
| Banerjee, G | 1 |
| Farmer, S | 1 |
| Hylton, B | 1 |
| Cowley, P | 1 |
| Eleftheriou, P | 1 |
| Porter, J | 1 |
| Werring, DJ | 1 |
| Kessler, RA | 1 |
| Li, X | 1 |
| Schwartz, K | 1 |
| Huang, H | 1 |
| Mealy, MA | 1 |
| Levy, M | 2 |
| Dessì, C | 2 |
| Leoni, G | 1 |
| Moi, P | 1 |
| Danjou, F | 1 |
| Follesa, I | 1 |
| Foschini, ML | 1 |
| Morittu, M | 1 |
| Zappu, A | 1 |
| Defraia, E | 1 |
| Bina, P | 1 |
| Cunico, A | 1 |
| Civolani, A | 1 |
| Podda, RA | 1 |
| Origa, R | 1 |
| Kuo, PH | 1 |
| Kuo, SH | 1 |
| Lo, RY | 1 |
| McLeod, C | 1 |
| Fleeman, N | 1 |
| Kirkham, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Chu, P | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Greenhalgh, J | 1 |
| Modell, B | 1 |
| Olujohungbe, A | 1 |
| Telfer, P | 1 |
| Walley, T | 1 |
| Alpendurada, F | 1 |
| Smith, GC | 1 |
| Carpenter, JP | 1 |
| Nair, SV | 1 |
| Tanner, MA | 1 |
| Banya, W | 1 |
| Galanello, R | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Tsironi, M | 1 |
| Polonifi, K | 1 |
| Deftereos, S | 1 |
| Farmakis, D | 1 |
| Andriopoulos, P | 1 |
| Moyssakis, I | 1 |
| Aessopos, A | 1 |
| Tavecchia, L | 1 |
| Masera, N | 1 |
| Russo, P | 1 |
| Cirò, A | 1 |
| Vincenzi, A | 1 |
| Vimercati, C | 1 |
| Masera, G | 1 |
| Kolnagou, A | 2 |
| Economides, C | 1 |
| Eracleous, E | 1 |
| Kontoghiorghes, GJ | 2 |
| Huang, YC | 1 |
| Chang, JS | 1 |
| Wu, KH | 1 |
| Peng, CT | 1 |
| al-Refaie, FN | 1 |
| Hershko, C | 1 |
| Hoffbrand, AV | 1 |
| Kosaryan, M | 1 |
| Olivieri, NF | 2 |
| Tondury, P | 1 |
| Wonke, B | 1 |
| Cermák, J | 1 |
| Brabec, V | 1 |
| Bichile, SK | 1 |
| Mehta, PJ | 1 |
| Parekh, SJ | 1 |
| Mehta, J | 1 |
| Chablani, A | 1 |
| Reporter, R | 1 |
| Singhal, S | 1 |
| Mehta, BC | 1 |
| Kowdley, KV | 1 |
| Tavill, AS | 1 |
| Lange, R | 2 |
| Lameijer, W | 2 |
| Slijkhuis, C | 1 |
| de Kaste, D | 1 |
| Kersten, MJ | 1 |
| Smeets, ME | 1 |
| Vreugdenhil, G | 1 |
| Roozendaal, KJ | 1 |
| Goudsmit, R | 2 |
| Klinz, C | 1 |
| Vullo, C | 1 |
| Di Palma, A | 1 |
| De Sanctis, V | 1 |
| Borgatti, L | 1 |
| Atti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for deferiprone and Hemosiderosis
| Article | Year |
|---|---|
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro | 2009 |
Long-term therapy with deferiprone.
Topics: Animals; Clinical Trials as Topic; Deferiprone; Drug Approval; Hemosiderosis; Humans; Iron; Iron Che | 1996 |
[Iron-chelating treatment].
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Erythropoiesis; Hemosiderosis; Humans; Iron; Iron Chel | 1989 |
2 trials available for deferiprone and Hemosiderosis
| Article | Year |
|---|---|
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com | 2006 |
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Female; Ferritins; Hemosiderosis; Huma | 1996 |
18 other studies available for deferiprone and Hemosiderosis
| Article | Year |
|---|---|
Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.
Topics: Adult; Aged; Agranulocytosis; Brain Diseases; Deferiprone; Female; Follow-Up Studies; Hemosiderosis; | 2020 |
Two-year observational study of deferiprone in superficial siderosis.
Topics: Adult; Aged; Aged, 80 and over; Brain; Deferiprone; Female; Hemosiderosis; Humans; Iron Chelating Ag | 2018 |
Ten years of iron chelation in a patient with superficial siderosis.
Topics: Aged; Deferiprone; Hemosiderosis; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Male; N | 2019 |
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam | 2015 |
Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis.
Topics: Brain Diseases, Metabolic; Deferiprone; Female; Hemosiderin; Hemosiderosis; Humans; Iron Chelating A | 2017 |
Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Chi-Square Distribution; Deferiprone; Deferoxamine; D | 2012 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Def | 2005 |
Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Failure; Hemosi | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
Topics: Adult; Agranulocytosis; Arthritis; beta-Thalassemia; Chemical and Drug Induced Liver Injury; Deferip | 1995 |
[Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)].
Topics: Administration, Oral; Deferiprone; Deferoxamine; Hemosiderosis; Humans; Iron Chelating Agents; Pyrid | 1994 |
Toxicity of oral iron chelator L1.
Topics: Adolescent; Adult; Blood Transfusion; Child; Clinical Trials as Topic; Deferiprone; Developing Count | 1993 |
Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoimmune Diseases; Blood Transfusion; Child; Deferipro | 1993 |
An oral treatment for iron overload in thalassemia?
Topics: Administration, Oral; Chelation Therapy; Deferiprone; Hemosiderosis; Humans; Iron Chelating Agents; | 1996 |
Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).
Topics: Administration, Oral; Deferiprone; Hemosiderosis; Humans; Iron; Pyridones; Quality Control | 1996 |
[Marked hemosiderosis in myelodysplastic syndrome].
Topics: Aged; Deferiprone; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Heart Failure; Hemosiderosis; | 1999 |
[Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Deferiprone; Female; Ferritins; Hemosiderosis; Humans; I | 1991 |